Cargando…

Novel Use of GLP-1 Receptor Agonist Therapy in HNF4A-MODY

Detalles Bibliográficos
Autores principales:	Broome, David T., Tekin, Zehra, Pantalone, Kevin M., Mehta, Adi E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2020
Materias:	e-Letters: Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245355/ https://www.ncbi.nlm.nih.gov/pubmed/32265191 http://dx.doi.org/10.2337/dc20-0012

Ejemplares similares

MON-646 Novel Use of GLP-1 Receptor Agonist Therapy in MODY-1 (HNF4A Mutation)
por: Broome, David Tyler, et al.
Publicado: (2020)

Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System
por: Wang, Tiansheng, et al.
Publicado: (2019)

SAT085 Oral Glucagon-like Peptide-1 Receptor Agonist As Adjuvant Treatment In HNF1A-MODY
por: Tyler Broome, David
Publicado: (2023)

Primary Care Health Care Use for Patients With Type 2 Diabetes During the COVID-19 Pandemic
por: Misra-Hebert, Anita D., et al.
Publicado: (2021)

Association of birthweight and penetrance of diabetes in individuals with HNF4A-MODY: a cohort study
por: Locke, Jonathan M., et al.
Publicado: (2021)

Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy
por: Fantasia, Kathryn L, et al.
Publicado: (2019)

Double Heterozygous Mutations Involving Both HNF1A/MODY3 and HNF4A/MODY1 Genes: A case report
por: Forlani, Gabriele, et al.
Publicado: (2010)

MON-130 Optimal Glycemic Control in a Patient with HNF1A MODY with GLP1-RA Monotherapy: Implications for Future Therapy
por: Fantasia, Kathryn, et al.
Publicado: (2019)

An Atypical HNF4A Mutation Which Does Not Conform to the Classic Presentation of HNF4A-MODY
por: Spiro, Andrew J., et al.
Publicado: (2018)

Efficacy of metformin versus sulfonylurea derivative in HNF4A-MODY
por: Oosterom, Nicole, et al.
Publicado: (2022)

Variants influencing age at diagnosis of HNF1A-MODY
por: Ludwig-Słomczyńska, Agnieszka H., et al.
Publicado: (2022)

Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts
por: Mirshahi, Uyenlinh L, et al.
Publicado: (2022)

RF28 | PSUN182 Risk of Pancreatitis After Glp-1 Receptor Agonist in Individuals With Known History of Pancreatitis
por: Kodali, Alimitha M, et al.
Publicado: (2022)

Cystatin C is not a good candidate biomarker for HNF1A-MODY
por: Nowak, Natalia, et al.
Publicado: (2012)

Circulating CD36 Is Reduced in HNF1A-MODY Carriers
por: Bacon, Siobhan, et al.
Publicado: (2013)

Circulating ghrelin level is higher in HNF1A–MODY and GCK–MODY than in polygenic forms of diabetes mellitus
por: Nowak, Natalia, et al.
Publicado: (2015)

Granuloma annulare and necrobiosis lipoidica in a patient with HNF1A-MODY
por: Brandes, Gabriela Irene Garcia, et al.
Publicado: (2022)

Genetic and Clinical Characterization of Patients with HNF1B-Related MODY in Croatia
por: Baretić, Maja, et al.
Publicado: (2023)

Two Cases of Diabetic Ketoacidosis in HNF1A-MODY Linked to Severe Dehydration: Is it time to change the diagnostic criteria for MODY?
por: Pruhova, Stepanka, et al.
Publicado: (2013)

Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019
por: Liu, Jiaqing, et al.
Publicado: (2020)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

A potentially serious adverse effect of GLP-1 receptor agonists
por: Lu, Jinmiao, et al.
Publicado: (2023)

Effect of Cost and Formulation on Persistence and Adherence to Initial Metformin Therapy for Type 2 Diabetes
por: Flory, James H., et al.
Publicado: (2020)

Incidence of Type 2 Diabetes in Patients With Chronic Hepatitis C Receiving Interferon-Based Therapy
por: Tsai, Ming-Chieh, et al.
Publicado: (2020)

Periprocedural Euglycemic Diabetic Ketoacidosis Associated With Sodium–Glucose Cotransporter 2 Inhibitor Therapy During Colonoscopy
por: Meyer, Emily J., et al.
Publicado: (2020)

The Relationship of Serum Soluble Receptor for Advanced Glycation End Products (sRAGE) and Carboxymethyl Lysine (CML) to the Incidence of Diabetic Nephropathy in Persons With Type 1 Diabetes
por: Klein, Ronald, et al.
Publicado: (2017)

Predictive Value of Admission Hemoglobin A(1c) on Inpatient Glycemic Control and Response to Insulin Therapy in Medicine and Surgery Patients With Type 2 Diabetes
por: Pasquel, Francisco J., et al.
Publicado: (2015)

Evaluation of the Clinical Impact of Dapagliflozin Discontinuation as Adjunctive Therapy for Patients With Type 1 Diabetes After Indication Withdrawal: A Two-Center Retrospective Study
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2023)

Incidence of HNF1A and GCK MODY Variants in a South African Population
por: Matsha, Tandi E, et al.
Publicado: (2020)

Role of Noninsulin Therapies Alone or in Combination in Chromosome 6q24-Related Transient Neonatal Diabetes: Sulfonylurea Improves but Does Not Always Normalize Insulin Secretion
por: Carmody, David, et al.
Publicado: (2015)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

Monocyte DPP4 Expression in Human Atherosclerosis Is Associated With Obesity and Dyslipidemia
por: Rao, Xiaoquan, et al.
Publicado: (2018)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Identification and precision therapy for three maturity-onset diabetes of the young (MODY) families caused by mutations in the HNF4A gene
por: Zhang, Juan, et al.
Publicado: (2023)

Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting
por: Wang, Tiansheng, et al.
Publicado: (2019)

Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
por: Li, Guangyao, et al.
Publicado: (2019)

High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes
por: McDonald, Tim J., et al.
Publicado: (2011)

MODY probability calculator for GCK and HNF1A screening in a multiethnic background population
por: Tarantino, Roberta Magalhães, et al.
Publicado: (2019)

Insights from basic adjunctive examinations of GCK‐MODY, HNF1A‐MODY, and type 2 diabetes: A systemic review and meta‐analysis
por: Liu, Jing, et al.
Publicado: (2023)

A Case of Novel Mutation of HNF1B in Maturity-onset Diabetes of the Young Type 5 (MODY5)
por: Jo, Wakako, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gbfmekmnj6nfe4g7lfbhdrh25f